Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Drugs
- Pharmaceuticals
- Therapeutic
- Pain
- Disease
- Nerve
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2893
License Grant
We have entered into an exclusive License Agreement relating to U.S. Patent No. 6,610,324 and its foreign equivalents, entitled Flupirtine in the treatment of fibromyalgia and related conditions. Flupirtine, an aminopyridine is a centrally acting nonopioid analgesic.
License Property
Flupirtine is an aminopyridine that functions as a centrally acting non-opioid analgesic that was originally used as an analgesic for acute and chronic pain.
Fibromyalgia is a common condition characterized by long-term, body-wide pain and tender points in joints, muscles, tendons, and other soft tissues. Fibromyalgia has also been linked to fatigue, morning stiffness, sleep problems, headaches, numbness in hands and feet, depression, and anxiety.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 2616
License Grant
We have entered into an exclusive License Agreement with the hospital, relating to U.S. Patent No. 6,610,324 and its foreign equivalents, entitled 'Flupirtine in the treatment of fibromyalgia and related conditions.
License Property
Fibromyalgia is a common condition characterized by long-term, body-wide pain and tender points in joints, muscles, tendons, and other soft tissues. Fibromyalgia has also been linked to fatigue, morning stiffness, sleep problems, headaches, numbness in hands and feet, depression, and anxiety.
IPSCIO Record ID: 1336
License Grant
The Licensee entered into an exclusive License Agreement with the Licensor, a teaching hospital.
License Property
The technology relates to U.S. Patent No. 6,610,324 and its foreign equivalents, entitled Flupirtine in the treatment of fibromyalgia and related conditions.
The due diligence requirements of the exclusive License Agreement were amended in April of 2010 and further amended by a Non-Disturbance Agreement that was signed with the Licensor, the Licensee and Meda.
Field of Use
The Licensee agreed to use its best efforts to commercialize oral flupirtine for the therapeutic uses embodied in the patent applications.
IPSCIO Record ID: 28675
License Grant
The Licensor and the Licensee entered into the Sub-License Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.
License Property
The Licensor will receive royalties on net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.
Pursuant to the Licensor's License Agreement with McLean Hospital, the Licensor paid 15% of the payment, that was netted against the revenues received from the Licensee.
The Licensor is also entitled to additional milestone payments upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and upon marketing approval.
The Sublicense Agreement provides that the Licensee will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia.
Field of Use
The rights granted apply to the medical industry.
IPSCIO Record ID: 1242
License Grant
In May of 2010, Company and its wholly owned subsidiary, the Licensor entered into a SubLicense Agreement pursuant to which the Licensor granted the Licensee of Sweden, an exclusive SubLicense to all of its patents covering the use of flupirtine for fibromyalgia.
Field of Use
The Agreement provides that the Licensee will assume all future development costs for the commercialization of flupirtine for fibromyalgia.
IPSCIO Record ID: 797
License Grant
The Licensor grants the Licensee exclusive, nontransferable Licenses for the Applications and the Patents; and the Trademarks, until the Patents expire.
The grant of each License hereunder includes the right to grant subLicenses to Related Companies.
License Property
Applications means PCT/US2009/062895, entitled Medication and Treatment for Disease.
Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.
Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure).[1] Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.
Field of Use
Trial usage of Feldetrex â„¢ has been used in patients with Multiple Sclerosis.
Licensee shall prominently use the Trademark on Licensed Products.
IPSCIO Record ID: 5599
License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.
IPSCIO Record ID: 203476
License Grant
The parties entered into a relationship whereby Licensor would develop reformulations of milnacipran and analogs of milnacipran, with a patient acceptance profile comparable or superior to the current formulations of milnacipran, pursuant to the terms and conditions of this Agreement.
Licensee hereby grants to Licensor during the R&D Term a non-exclusive, non-sublicensable, non-transferable license to the Licensee for use by Licensor only for the performance of its obligations under this Agreement. Licensor agrees that it shall not use the Licensee for any other purposes.
License Property
Licensor has expertise in developing reformulations of existing products and new products which are analogs of existing products
Licensee Patents shall mean, to the extent necessary or useful for the development of Reformulated Products or New Products or otherwise for purposes of the R&D Plan, (a) all foreign and domestic (i) patents issued or existing as of the Effective Date which Licensee Controls; (ii) patents issuing from patent applications that are pending as of the Effective Date.
Reformulated Product shall mean any Product which is developed by Licensor under this Agreement and contains milnacipran in a formulation that is different than the Existing Product, but that does not meet the criteria for a New Product.
Milnacipran is immediate release formulation in capsule form containing 25 mg and 50 mg of milnacipran and the existing slow release fo1mulation containing 120 mg of milnacipran, as set forth in PCT published international application WO 98/08495.
Field of Use
Milnacipran is used to treat pain caused by a condition called fibromyalgia that affects the muscles, tendons, ligaments, and supporting tissues. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way your brain processes pain signals.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
